FDA grants priority review to Genentech's Gazyva for kidney disease
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), said the U.S. Food and Drug Administration has ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
